HomeInsightsResults

Wockhardt Ltd Quarterly Result

Wockhardt Ltd Quarterly Result

stocks purchased

₹ 3.3 Cr

Volume Transacted

(Nov 22, 2024)

stocks purchased

26.7 K

Stocks Traded

(Nov 22, 2024)

Last Updated on: Nov 22, 2024

Image

Wockhardt Ltd

NSE: WOCKPHARMA

Net Profit

₹ -16

Last updated on: Nov 22, 2024

Key Highlights

  • The revenue of Wockhardt Ltd for the Sep '24 is ₹ 818 crore as compare to the Jun '24 revenue of ₹ 769 crore. This represent the growth of 6.3719115%.
  • The ebitda of Wockhardt Ltd for the Sep '24 is ₹ 119 crore as compare to the Jun '24 ebitda of ₹ 121 crore. This represent the decline of -1.6528926%.
  • The net profit of Wockhardt Ltd for the Sep '24 is ₹ -16 crore as compare to the Jun '24 net profit of ₹ -16 crore. This represent the decline of -0%.

Results Analysis

Market Price of Wockhardt Ltd

1M

1Y

3Y

5Y

Monitoring Wockhardt Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Market Price

Date
leftPrice (₹)right
22 Nov 20241230.95
21 Nov 20241172.35
19 Nov 20241186.95
18 Nov 20241136.5
14 Nov 20241170.85
13 Nov 20241190.15
12 Nov 20241181.5
11 Nov 20241222.3
08 Nov 20241233.85
07 Nov 20241206.5

Historical Revenue of Wockhardt Ltd

No data available

* All values are in crore

Historical EBITDA of Wockhardt Ltd

No data available

* All values are in crore

Historical Net Profit of Wockhardt Ltd

No data available

* All values are in crore

Wockhardt Ltd News Hub

News

Wockhardt to conduct board meeting

Wockhardt will hold a meeting of the Board of Directors of the Company on 13 November 2024...

Read more

08 Nov 202416:42

News

Wockhardt slumps on launching QIP at discount

The floor price indicates a steep discount of 8.5% over the stock's closing price on Wedne...

Read more

07 Nov 202414:38

News

Wockhardt files its Aspart insulin injection with DCGI

Wockhardt announced the filing of its fast-acting insulin analog, Aspart injection (ASPARA...

Read more

16 Oct 202409:21

News

Wockhardt's once-a-day antibiotic drug 'WCK 6777' successfully concludes Phase I study

Wockhardt is advancing the development of several new antibiotics aimed at combating diffi...

Read more

07 Oct 202414:59

News

Wockhardt announces cessation of director

Wockhardt announced that Tasneem Vikram Singh Mehta (DIN: 05009664) ceased to be Independe...

Read more

30 Sep 202418:20

News

Wockhardt's investigational drug, Zaynich' demonstrates its ability to manage complex infections

In the past year, Wockhardt's investigational drug, Zaynich' (Zidebactam/Cefepime), has su...

Read more

19 Sep 202409:15

Document

Annual Reports

Annual Report 2024

dropdown
download

Credit Ratings

Credit Report 2024

dropdown
download

Concalls

Feb 2024

PPT

Mar 2022

PPT

FAQ's For Wockhardt Ltd Quarterly Result

What is the EPS of Wockhardt Ltd stock?

The Earnings Per Share (EPS) of Wockhardt Ltd is 0.0. An EPS is the amount of net income attributed to each share of a common stock.

How is Wockhardt Ltd EPS calculated?

The EPS of Wockhardt Ltd is calculated by dividing the net income by the number of outstanding shares. The formula is EPS = (Net Income - Dividends on Preferred Stock) / Average Outstanding Shares.

How often does Wockhardt Ltd report its EPS?

Wockhardt Ltd typically reports its EPS quarterly and annually, in conjunction with its financial statements and earnings reports.

What factors can influence Wockhardt Ltd EPS?

Factors that influence the EPS of Wockhardt Ltd include revenue changes, cost fluctuations, operational efficiency, tax rates, and one-time gains or losses.

Can Wockhardt Ltd EPS growth indicate future performance?

Yes, consistent growth in Wockhardt Ltd EPS can suggest strong financial health and effective management, potentially indicating positive future performance.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
50yearstrust

Unlimited trading at just

Rs. 399

Rs. 199*